Bosun Asset Management LLC Purchases 44,810 Shares of AxoGen, Inc. (NASDAQ:AXGN)

Bosun Asset Management LLC lifted its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 125.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 80,448 shares of the medical equipment provider’s stock after purchasing an additional 44,810 shares during the quarter. Bosun Asset Management LLC’s holdings in AxoGen were worth $1,326,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of AXGN. R Squared Ltd bought a new position in AxoGen during the fourth quarter valued at $30,000. US Bancorp DE purchased a new stake in shares of AxoGen during the 4th quarter valued at about $30,000. Harvest Fund Management Co. Ltd bought a new position in shares of AxoGen in the 4th quarter valued at about $93,000. Fox Run Management L.L.C. purchased a new position in AxoGen in the fourth quarter worth about $169,000. Finally, Sei Investments Co. bought a new stake in AxoGen during the fourth quarter worth approximately $188,000. Institutional investors own 80.29% of the company’s stock.

Insider Buying and Selling at AxoGen

In other news, insider Erick Wayne Devinney sold 15,111 shares of AxoGen stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total transaction of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares of the company’s stock, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the sale, the director now owns 97,899 shares of the company’s stock, valued at $1,959,937.98. The trade was a 4.86 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

AXGN has been the subject of several analyst reports. Canaccord Genuity Group raised their price objective on AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Lake Street Capital began coverage on AxoGen in a research report on Monday, March 17th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $24.00 price objective on shares of AxoGen in a research report on Wednesday, March 5th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen presently has an average rating of “Buy” and an average target price of $22.60.

AxoGen Trading Down 2.2 %

Shares of NASDAQ AXGN opened at $16.75 on Tuesday. AxoGen, Inc. has a fifty-two week low of $5.55 and a fifty-two week high of $21.00. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The company has a market cap of $742.76 million, a price-to-earnings ratio of -52.34 and a beta of 1.19. The business’s 50 day moving average price is $17.16 and its 200-day moving average price is $16.31.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.